Calidi Biotherapeutics (CLDI) outlines 2025 updates and 2026 IND plan

Rhea-AI Filing Summary

Calidi Biotherapeutics, Inc. filed a current report describing a new press release that shares corporate updates for the fiscal year ended December 31, 2025 and outlines key operational plans for 2026. The release also includes preliminary, unaudited financial information that is still subject to completion of year-end closing and audit procedures.

The company highlights forward-looking plans, including its intention to submit an Investigational New Drug application by the end of 2026. All preliminary figures may change once the audit is completed, and the information in this report is furnished rather than filed for securities law purposes.

8-K Event Classification

3 items: 2.02, 8.01, 9.01

3 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding 8-K Material Events →

Accepted by SEC EDGAR 01/28/2026 - 05:54 PM Learn about SEC filing dates

false 0001855485 0001855485 2026-01-28 2026-01-28 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 28, 2026

CALIDI BIOTHERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-40789		86-2967193
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

4475 Executive Drive, Suite 200, San Diego, California		92121
(Address of principal executive offices)		(Zip Code)

(858) 794-9600

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Title of Each Class		Trading Symbol(s)		Name of Each Exchange on Which Registered
Common stock, par value $0.0001 per share		CLDI		NYSE American LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operation and Financial Condition

On January 28, 2026, Calidi Biotherapeutics, Inc. (the “Company”) issued a press release providing corporate updates for the fiscal year ended December 31, 2025, and updates on key operational initiatives for fiscal year 2026, which also includes certain preliminary, unaudited financial information.

A copy of the press release is incorporated herein by reference and is furnished as Exhibit 99.1. The preliminary, unaudited financial information included in the press release is based on information available to management as of the date of the press release and is subject to completion of the Company’s financial closing procedures and adjustments, including completion of the audit of the Company’s financial statements for the fiscal year ended December 31, 2025. Accordingly, such information may differ from the final results to be reflected in the Company’s audited financial statements and other filings with the Securities and Exchange Commission.

The information under this Item 2.02 is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 8.01 Other Events

On January 28, 2026, the Company issued a press release providing corporate updates for the fiscal year ended December 31, 2025, and updates on key operational initiatives for fiscal year 2026, which also includes certain preliminary, unaudited financial information. A copy of the press release is included as Exhibit 99.1 hereto and is incorporated by reference herein.

Forward Looking Statements

This Current Report on Form 8-K (including Exhibit 99.1) contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, statements regarding (i) preliminary or unaudited financial information and the Company’s expectations regarding the completion of its financial closing procedures and audit for the fiscal year ended December 31, 2025, including the anticipated finalization of results, (ii) the Company’s plans, strategies, priorities and key operational initiatives for fiscal year 2026, including the Company’s plan to submit an Investigational New Drug (“IND”) application by the end of 2026. Forward-looking statements are generally identified by words such as “may,” “will,” “should,” “could,” “would,” “expect,” “intend,” “plan,” “anticipate,” “estimate,” “believe,” “continue,” “potential,” “target,” “project,” “forecast,” and similar expressions, or the negative of these terms.

Forward-looking statements are based on management’s current expectations and assumptions as of the date hereof and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. With respect to the preliminary, unaudited financial information, actual results may differ, and such differences may be material, as a result of the completion of the Company’s financial closing procedures and audit, including the identification of additional information that becomes available, completion of management’s review, final adjustments, and other developments that may arise between the date of the press release and the date that the Company’s financial statements are finalized. With respect to the Company’s fiscal year 2026 initiatives, including the timing and ability to submit an IND application by the end of 2026, actual results may differ materially due to, among other things, the timing, cost and results of research and development activities and preclinical studies; interactions with, and the timing of feedback from, regulatory authorities; changes in applicable laws or regulations; manufacturing and supply chain matters; the availability of capital and other resources; and changes in business, market, economic or competitive conditions. Additional factors that could cause actual results to differ materially are described under the heading “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and subsequent filings with the Securities and Exchange Commission.

The Company undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this report, except as required by law.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit		Exhibit Description
99.1		Press Release dated January 28, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	CALIDI BIOTHERAPEUTICS, INC.
Dated: January 28, 2026
	By:	/s/ Andrew Jackson
	Name:	Andrew Jackson
	Title:	Chief Financial Officer

FAQ

What did Calidi Biotherapeutics (CLDI) disclose in its latest 8-K filing?

Calidi Biotherapeutics disclosed that it issued a press release with corporate updates for 2025 and key operational plans for 2026, including preliminary unaudited financial information. The details are furnished as an exhibit and remain subject to final year-end closing and audit procedures.

Does the Calidi Biotherapeutics (CLDI) 8-K include final 2025 financial results?

No, the filing references preliminary, unaudited 2025 financial information contained in a press release. Management notes these figures may change after completion of financial closing procedures, audit adjustments, and final review before being reflected in audited statements and future regulatory filings.

What 2026 operational plans does Calidi Biotherapeutics (CLDI) highlight?

Calidi Biotherapeutics highlights key operational initiatives for fiscal 2026, including its plan to submit an Investigational New Drug application by the end of 2026. These plans are forward-looking and subject to various risks, regulatory interactions, funding availability, and changing business or market conditions.

How is the information in Calidi Biotherapeutics’ 8-K treated under securities laws?

The company states the Item 2.02 information is furnished, not filed, under the Exchange Act. This means it is not subject to Section 18 liability and is not automatically incorporated by reference into other Securities Act or Exchange Act filings unless specifically referenced.

What risks and uncertainties does Calidi Biotherapeutics (CLDI) cite for its forward-looking statements?

The company notes that forward-looking statements involve significant risks and uncertainties, including audit completion effects on preliminary results, research and development outcomes, regulatory feedback and timing, manufacturing and supply issues, capital availability, and broader business, economic, or competitive changes described in its Form 10-K risk factors.

Where can investors find the detailed Calidi Biotherapeutics (CLDI) corporate update?

The detailed corporate and preliminary financial update is in a press release attached as Exhibit 99.1 to the 8-K. The exhibit provides year-end 2025 information and outlines initiatives for 2026, and is incorporated by reference into the current report.